Purpose To evaluate the clinical out come and quantify histologically the amount of microscopic internal limiting membrane(ILM)and epiretinal membrane(ERM)pre-sent in ILM and ERM specimens obtained from ERM surgery.De...Purpose To evaluate the clinical out come and quantify histologically the amount of microscopic internal limiting membrane(ILM)and epiretinal membrane(ERM)pre-sent in ILM and ERM specimens obtained from ERM surgery.Design Interventional con secutive case series.Methods Patients scheduled for ERM s urgery were re-cruited prospectively.Pars plana v itrectomy,removal of ERM,and ILM peeling with indocyanin e green(ICG)staining were performed in all patie nts.Epiretinal mem-brane and ILM specimens were sent for histologic exam-ination.The amount of ERM present in ILM specimens and the amount of ILM present in ERM sp ecimens were quantified by manual counting.Outc ome measures in-clude change in best corrected visual acuity(BCVA),proportion of cases with 2or more lin es of visual im-provement,anatomic outcome,proportions of microscopic ERM within ILM,and microscopic ILM w ithin ERM.Results Eighteen eyes in 18patients were operated with a mean follow-up of 19.3months.There were 13primary ERMs and five secondary ERMs.The mea n logMAR BC-VA improved from 0.83preoperatively to 0.49postop-eratively(P<0.001).The mean lines of improvement in BCVA was 3.3lines with 14patients(77.8%)who had 2or more lines of BCVA improvemen t.Histologic e-valuation of the specimens showed no significant correla-tion with the final BCVA of 20/50or better.Eleven(61.1%)of the ILM specimens showed various a mount of microscopic ERM and 16(88.9%)of the ERM speci-mens showed various amount of ILM fra gments.The mean proportion of ERM within ILM specime ns was 4.69%and that of ILM within ERM specimens was 51.5%.No sig-nificant recurrence of ERM was found.Conclusion Re-currence of ERM may be minimized by re moving residual microscopic ERM present on the ILM.I ndocyaninegreen-assisted ILM peeling in ERM su rgery appears to have favorable visual and anatomic o utcomes.展开更多
Objective To assess whether iris color and eyelash changes occur with the use of unoprostone for2years.Design The 2clinical trials described herein we re prospective,random-ized,double-masked,active-contr olled,parall...Objective To assess whether iris color and eyelash changes occur with the use of unoprostone for2years.Design The 2clinical trials described herein we re prospective,random-ized,double-masked,active-contr olled,parallel group,multicenter studies.Participants A total of 1131patients with primary open-angle glaucoma or ocular hypertension participated in 2clinical trials an d received either uno-prostone isopropyl 0.15%(659),timolol maleate 0.5%(331),or betaxolol hydrochloride 0.5%(141),1drop per eye twice daily for up to 24months.Methods Color photographs(1:1magnification)were taken of the iris andeyelid of each patient at baseline an d at regular intervals thereafter through month 24using a s tandardized camera system.Photography included 7view s of each eye plus a calibration photograph and a patien t identification photo-graph,for a total of 16photographs p er patient per visit.Two independent (masked)readers subjectively compared baseline iris colors to subsequent v isits.Side view pho-tographs of the upper and lower eyela shes were used for the eyelash length analysis,with each h aving sufficient depth of field and a sufficient number of eyelashes in focus.Similarly,frontal eyelash views we re used for the eyelash density analysis.Main outcome measures Changes from baseline in iris color and eyelash le ngth and density within and between treatment groups.Resul ts Seven cases of iris color change(1.06%)were confirmed in patients treated with unoprostone for up to 24months;no confirmed cases were reported in the timolol or betax olol groups.In the unoprostone group,cases of iris color change were con-firmed at months 12(1case),18(2cases),and 24(4cases).No clinically relevant differences were observed among treatment groups for changes f rom baseline in eye-lash length or density.Conclusion A lthough iris hyper pigmentation and abnormal eyelash c hanges may occur after treatment with unoprostone,the incidence of these events appears to be low in the 2-year clinic al study.展开更多
文摘Purpose To evaluate the clinical out come and quantify histologically the amount of microscopic internal limiting membrane(ILM)and epiretinal membrane(ERM)pre-sent in ILM and ERM specimens obtained from ERM surgery.Design Interventional con secutive case series.Methods Patients scheduled for ERM s urgery were re-cruited prospectively.Pars plana v itrectomy,removal of ERM,and ILM peeling with indocyanin e green(ICG)staining were performed in all patie nts.Epiretinal mem-brane and ILM specimens were sent for histologic exam-ination.The amount of ERM present in ILM specimens and the amount of ILM present in ERM sp ecimens were quantified by manual counting.Outc ome measures in-clude change in best corrected visual acuity(BCVA),proportion of cases with 2or more lin es of visual im-provement,anatomic outcome,proportions of microscopic ERM within ILM,and microscopic ILM w ithin ERM.Results Eighteen eyes in 18patients were operated with a mean follow-up of 19.3months.There were 13primary ERMs and five secondary ERMs.The mea n logMAR BC-VA improved from 0.83preoperatively to 0.49postop-eratively(P<0.001).The mean lines of improvement in BCVA was 3.3lines with 14patients(77.8%)who had 2or more lines of BCVA improvemen t.Histologic e-valuation of the specimens showed no significant correla-tion with the final BCVA of 20/50or better.Eleven(61.1%)of the ILM specimens showed various a mount of microscopic ERM and 16(88.9%)of the ERM speci-mens showed various amount of ILM fra gments.The mean proportion of ERM within ILM specime ns was 4.69%and that of ILM within ERM specimens was 51.5%.No sig-nificant recurrence of ERM was found.Conclusion Re-currence of ERM may be minimized by re moving residual microscopic ERM present on the ILM.I ndocyaninegreen-assisted ILM peeling in ERM su rgery appears to have favorable visual and anatomic o utcomes.
文摘Objective To assess whether iris color and eyelash changes occur with the use of unoprostone for2years.Design The 2clinical trials described herein we re prospective,random-ized,double-masked,active-contr olled,parallel group,multicenter studies.Participants A total of 1131patients with primary open-angle glaucoma or ocular hypertension participated in 2clinical trials an d received either uno-prostone isopropyl 0.15%(659),timolol maleate 0.5%(331),or betaxolol hydrochloride 0.5%(141),1drop per eye twice daily for up to 24months.Methods Color photographs(1:1magnification)were taken of the iris andeyelid of each patient at baseline an d at regular intervals thereafter through month 24using a s tandardized camera system.Photography included 7view s of each eye plus a calibration photograph and a patien t identification photo-graph,for a total of 16photographs p er patient per visit.Two independent (masked)readers subjectively compared baseline iris colors to subsequent v isits.Side view pho-tographs of the upper and lower eyela shes were used for the eyelash length analysis,with each h aving sufficient depth of field and a sufficient number of eyelashes in focus.Similarly,frontal eyelash views we re used for the eyelash density analysis.Main outcome measures Changes from baseline in iris color and eyelash le ngth and density within and between treatment groups.Resul ts Seven cases of iris color change(1.06%)were confirmed in patients treated with unoprostone for up to 24months;no confirmed cases were reported in the timolol or betax olol groups.In the unoprostone group,cases of iris color change were con-firmed at months 12(1case),18(2cases),and 24(4cases).No clinically relevant differences were observed among treatment groups for changes f rom baseline in eye-lash length or density.Conclusion A lthough iris hyper pigmentation and abnormal eyelash c hanges may occur after treatment with unoprostone,the incidence of these events appears to be low in the 2-year clinic al study.
